---
title: "Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294366513.md"
description: "Cingulate Inc. published Phase 3 trial results for its ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. The study demonstrated meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. With a favorable safety profile, Cingulate plans to advance CTx-1301 toward potential regulatory filing and commercialization."
datetime: "2026-07-30T12:33:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294366513.md)
  - [en](https://longbridge.com/en/news/294366513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294366513.md)
---

# Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology

-   Cingulate disclosed open-access publication of Phase 3 results for ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. \* Results were already presented in the peer-reviewed paper, not flagged for a future medical meeting. \* Trial showed meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. \* Safety profile was described as favorable, reinforcing plans to advance CTx-1301 toward potential regulatory filing and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800711) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CING.US](https://longbridge.com/en/quote/CING.US.md)
- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs](https://longbridge.com/en/news/295537403.md)
- [Cingulate Q2 FY26 net loss widens to $5.87 million; SG&A more than doubles to $3.93 million](https://longbridge.com/en/news/295798941.md)
- [13:00 ETChildren's Miracle Network and Black Dragon Capital Partner to Expand Digital Giving Opportunities for Credit Union Members](https://longbridge.com/en/news/295563058.md)
- [Bavarian Nordic says Phase 2 trial supports EU approval of IMVANEX mpox vaccine in children 2-11](https://longbridge.com/en/news/295186449.md)
- [Baby products company Frida is expanding into kids’ personal care](https://longbridge.com/en/news/295533108.md)